Cargando…

Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment

BACKGROUND: Unfractionated heparin is commonly used for anticoagulation in extracorporeal membrane oxygenation (ECMO). Several studies have shown that nafamostat mesilate (NM) has comparable clinical outcomes to unfractionated heparin. This study compared anticoagulation with NM and heparin in a lar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Sung Joon, Han, Woosik, Song, Hee-Jung, Kim, Cuk-Seong, Jeong, Seong-Mok, Kang, Min Woong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Thoracic and Cardiovascular Surgery 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894575/ https://www.ncbi.nlm.nih.gov/pubmed/29662809 http://dx.doi.org/10.5090/kjtcs.2018.51.2.114

Ejemplares similares

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Utility and safety of nafamostat mesilate for anticoagulation in dogs
por: Isayama, Noriko, et al.
Publicado: (2022)

Nafamostat Mesilate: Can It Be Used as a Conduit Preserving Agent in Coronary Artery Bypass Surgery?
por: Yoon, Yoo Sang, et al.
Publicado: (2013)

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

Nafamostat Mesilate Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production
por: Kang, Min-Woong, et al.
Publicado: (2015)

Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway
por: Choi, Sujeong, et al.
Publicado: (2016)

The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
por: Kim, Joo Seong, et al.
Publicado: (2022)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial
por: Choi, Ji-Young, et al.
Publicado: (2015)

Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?
por: Koniari, Ioanna, et al.
Publicado: (2017)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
por: Uwagawa, Tadashi, et al.
Publicado: (2022)

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis
por: Lin, Yao, et al.
Publicado: (2022)

Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells
por: Sugano, Hiroshi, et al.
Publicado: (2018)

The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations
por: Chen, Xuanmao, et al.
Publicado: (2010)

Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition
por: Chen, Tao, et al.
Publicado: (2014)

Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells
por: Takada, Naoki, et al.
Publicado: (2021)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

Anticoagulation on extracorporeal membrane oxygenation (ECMO)
por: Khilnani, Praveen
Publicado: (2017)

Preventing thrombosis in a COVID‐19 patient by combined therapy with nafamostat and heparin during extracorporeal membrane oxygenation
por: Doi, Shunichi, et al.
Publicado: (2020)

Glycogen synthase kinase‐3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells
por: Haruki, Koichiro, et al.
Publicado: (2017)

Endogenous glycosaminoglycan anticoagulation in extracorporeal membrane oxygenation
por: MacLaren, Graeme, et al.
Publicado: (2014)

Sodium alginate-hydrogel coatings on extracorporeal membrane oxygenation for anticoagulation
por: Gao, Wenqing, et al.
Publicado: (2022)

Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials
por: Xie, Yu, et al.
Publicado: (2023)

Outcomes of Extracorporeal Membrane Oxygenation in Children: An 11-Year Single-Center Experience in Korea
por: Kim, Hongsun, et al.
Publicado: (2017)

Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study
por: Lee, Yong Kyu, et al.
Publicado: (2014)

Use of argatroban in combination with nafamostat mesilate in open-heart surgery for a pediatric patient with heparin-induced thrombocytopenia type II: a case report
por: Kawamoto, Shuji, et al.
Publicado: (2020)

How to manage anticoagulation during extracorporeal membrane oxygenation
por: Levy, Jerrold H., et al.
Publicado: (2022)

Management of Anticoagulation during Extracorporeal Membrane Oxygenation in Children
por: Chegondi, Madhuradhar, et al.
Publicado: (2022)

Anticoagulation Therapy during Extracorporeal Membrane Oxygenator Support in Pediatric Patients
por: Cho, Hwa Jin, et al.
Publicado: (2017)

Erratum: Outcomes of Extracorporeal Membrane Oxygenation in Children: An 11-Year Single-Center Experience in Korea
por: Kim, Hongsun, et al.
Publicado: (2021)

Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation
por: Burstein, Barry, et al.
Publicado: (2019)

Correction: Hiroshi Sugano et al. Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers 2018, 10, 386
por: Sugano, Hiroshi, et al.
Publicado: (2019)

AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study
por: Hirayama, Takahiro, et al.
Publicado: (2017)

Anticoagulation in COVID-19-positive Patients on Venovenous Extracorporeal Membrane Oxygenation
por: Patel, Mayuri, et al.
Publicado: (2022)

Context-Responsive Anticoagulation Reduces Complications in Pediatric Extracorporeal Membrane Oxygenation
por: Lin, John C., et al.
Publicado: (2021)

Anticoagulation Strategies during Extracorporeal Membrane Oxygenation: A Narrative Review
por: Rajsic, Sasa, et al.
Publicado: (2022)

Anticoagulation Management during Extracorporeal Membrane Oxygenation—A Mini-Review
por: Burša, Filip, et al.
Publicado: (2022)

Prevalence and Impact of Lupus Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation
por: Kornfehl, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dsvgsrd4d6pmo30o29e7a3fjcn